

24th September, 2026

To,

The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. Scrip Code: 539523	National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai 400 051. Scrip Symbol: ALKEM
---	--

Sub: Disclosure under Regulation 30(2) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (“SEBI LODR Regulations”): Change in Key Managerial Personnel – Resignation of Chief Financial Officer

Dear Sir(s)/Madam,

Pursuant to Regulation 30 of SEBI LODR Regulations, we wish to inform you that Mr. Nitin Agrawal has resigned on 30th July, 2026 from the position of Chief Financial Officer & Key Managerial Personnel of the Company to pursue new professional opportunities. Accordingly, Mr. Nitin Agrawal shall cease to hold Senior Management Position of the Company effective from 30th September, 2026.

Further, the details as required in terms of Regulation 30 read with Schedule III of the SEBI LODR Regulations and SEBI Master Circular bearing No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026 is provided in Annexure I to this letter and a copy of resignation letter dated 30th July, 2026 tendered by Mr. Nitin Agrawal as the Chief Financial Officer (CFO) is enclosed herewith as Annexure II.

The above information is also available on the website of the Company at www.alkemlabs.com.

Kindly take the same on your records.

Sincerely,
For **Alkem Laboratories Limited**

Manish Narang
President – Legal, Company Secretary & Compliance Officer

Encl: a/a

Annexure I

(Disclosure in terms of Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular bearing Ref.No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026)

Sr. No.	Particulars	Details
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Resignation
2.	Date of appointment/ re-appointment/ cessation (as applicable) and term of appointment/ reappointment	Mr. Nitin Agrawal shall cease to be Senior Management Personnel, effective from 30 th September, 2026
3.	Brief Profile	Not Applicable
4.	Disclosure of relationships between directors	Not Applicable

Annexure II

To

Date: 30th July, 2026

The Chairman
Alkem Laboratories Limited
Alkem House, Senapati Bapat Marg,
Lower Parel, Mumbai – 400013

Sub: Resignation from the position of Chief Financial Officer

Dear Sir,

I am writing to formally resign from my position as Chief Financial Officer of Alkem Laboratories Limited.

Serving as CFO of Alkem Laboratories over the last few years has been a great honour, and one I will always look back on with gratitude.


I am deeply thankful to you and to the Board of Directors for entrusting me with so many of the group's strategic mandates, including building the MedTech business from the ground up, the acquisition of Adroit, the creation of Alkem Wellness, the formation of the Saudi joint venture and the acquisition of Bombay Ortho. I was equally privileged to support the liquidation of idle assets such as the Indore SEZ plant, the enhancement of rate of returns on treasury income and the implementation of the new UCPMP marketing guidelines in the domestic market and Most recently lead the acquisition of Occlutech

This has not been an easy decision. However, I have chosen to step down to pursue new professional opportunities that align more closely with my long-term professional and personal growth.

I remain fully committed to supporting the management in ensuring a seamless handover of all ongoing strategic initiatives, and will serve through 30 September 2026.

I wish you, the Board, and the entire Alkem family continued success in the years ahead.

With sincere regards,



Nitin Agrawal

Chief Financial Officer

Alkem Laboratories Limited